Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study
信迪利单抗(抗PD-1抗体)联合西达米德(组蛋白去乙酰化酶抑制剂)治疗复发或难治性结外自然杀伤T细胞淋巴瘤(SCENT):一项Ib/II期研究
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-024-01825-0
Gao, Yan; He, Haixia; Li, Xueping; Zhang, Liling; Xu, Wei; Feng, Ru; Li, Wenyu; Xiao, Yin; Liu, Xinxiu; Chen, Yu; Wang, Xiaoxiao; Bai, Bing; Wu, Huijing; Cai, Qingqing; Li, Zhiming; Li, Jibin; Lin, Suxia; He, Yanxia; Ping, Liqin; Huang, Cheng; Mao, Jiaying; Chen, Xiujin; Zhao, Baitian; Huang, Huiqiang
表观遗传
T细胞
淋巴瘤
T细胞
乙酰化
细胞生物学
PD-1
免疫/内分泌